AMF Pensionsforsakring AB lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 6.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 692,614 shares of the medical research company’s stock after selling 46,806 shares during the period. Amgen makes up approximately 1.3% of AMF Pensionsforsakring AB’s investment portfolio, making the stock its 12th largest position. AMF Pensionsforsakring AB’s holdings in Amgen were worth $113,637,000 at the end of the most recent quarter.
A number of other large investors also recently modified their holdings of the stock. Norges Bank bought a new stake in shares of Amgen during the fourth quarter valued at $1,016,913,000. FMR LLC boosted its stake in shares of Amgen by 11.3% in the fourth quarter. FMR LLC now owns 40,789,786 shares of the medical research company’s stock valued at $5,963,875,000 after buying an additional 4,144,154 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main bought a new stake in shares of Amgen during the fourth quarter valued at $275,209,000. Asset Management One Co. Ltd. boosted its stake in shares of Amgen by 426.2% in the fourth quarter. Asset Management One Co. Ltd. now owns 1,331,811 shares of the medical research company’s stock valued at $194,885,000 after buying an additional 1,078,691 shares in the last quarter. Finally, State Street Corp boosted its stake in shares of Amgen by 2.8% in the fourth quarter. State Street Corp now owns 34,308,673 shares of the medical research company’s stock valued at $5,016,268,000 after buying an additional 919,966 shares in the last quarter. Institutional investors own 78.84% of the company’s stock.
Shares of Amgen Inc. (NASDAQ:AMGN) opened at 172.50 on Friday. Amgen Inc. has a 1-year low of $133.64 and a 1-year high of $184.21. The stock has a market cap of $126.86 billion, a P/E ratio of 16.38 and a beta of 1.37. The company has a 50 day moving average price of $160.31 and a 200 day moving average price of $161.40. Amgen also saw unusually large options trading activity on Wednesday. Stock investors bought 2,287 call options on the company. This is an increase of approximately 207% compared to the average daily volume of 746 call options.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Wednesday, April 26th. The medical research company reported $3.15 EPS for the quarter, topping analysts’ consensus estimates of $3.00 by $0.15. The company had revenue of $5.46 billion during the quarter, compared to the consensus estimate of $5.60 billion. Amgen had a net margin of 34.42% and a return on equity of 29.37%. Amgen’s revenue for the quarter was down 1.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.90 earnings per share. On average, equities analysts anticipate that Amgen Inc. will post $12.44 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by sleekmoney and is the sole property of of sleekmoney. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://sleekmoney.com/amgen-inc-amgn-shares-sold-by-amf-pensionsforsakring-ab/1936152.html.
Several equities research analysts recently weighed in on AMGN shares. Jefferies Group LLC cut Amgen from a “buy” rating to a “hold” rating and dropped their target price for the company from $194.00 to $180.00 in a report on Wednesday, April 5th. Vetr upgraded Amgen from a “buy” rating to a “strong-buy” rating and set a $184.82 target price for the company in a report on Monday, March 27th. Credit Suisse Group restated a “hold” rating and set a $178.00 target price on shares of Amgen in a report on Tuesday, April 4th. Cowen and Company reaffirmed an “outperform” rating and set a $209.00 price target on shares of Amgen in a research report on Wednesday, April 19th. Finally, Mizuho set a $195.00 price target on Amgen and gave the company a “buy” rating in a research report on Thursday, March 16th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating, ten have given a buy rating and three have assigned a strong buy rating to the stock. Amgen has a consensus rating of “Buy” and a consensus target price of $184.94.
In related news, SVP Cynthia M. Patton sold 2,922 shares of the business’s stock in a transaction that occurred on Wednesday, May 24th. The shares were sold at an average price of $154.40, for a total value of $451,156.80. Following the completion of the transaction, the senior vice president now owns 24,214 shares of the company’s stock, valued at $3,738,641.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.20% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/amgen-inc-amgn-shares-sold-by-amf-pensionsforsakring-ab/1936152.html
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.